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The use of in vivo probe substrates is a widely ac-cepted method of evaluating cytochrome P450 ac-
tivity in individuals.1,2 By administering a suitable sub-
strate for the enzyme in question, enzymatic activity
can be evaluated by comparing total or fractional clear-
ance, metabolic ratios of parent compounds, and/or
their metabolites in the plasma, urine, saliva or breath
of an individual.
The plasma clearance of intravenously adminis-
tered midazolam, a benzodiazepine used clinically for
conscious sedation, has been used as an in vivo marker
of hepatic CYP3A activity. Thummel and colleagues
were the first to investigate the utility of midazolam as a
phenotyping probe for CYP3A.3-5 Importantly, they ob-
served a strong correlation between the systemic clear-
ance of midazolam and in vitro hepatic CYP3A activity.
This was the basis for the use of this pharmacokinetic
parameter as a phenotypic measure of hepatic CYP3A
activity.5,6
To calculate systemic clearance using midazolam,
the area under the curve (AUC0-∞) of midazolam must
be determined. This requires multiple plasma samples
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Midazolam clearance is used to phenotype hepatic CYP3A
activity but requires multiple plasma samples following a sin-
gle intravenous dose. The authors evaluated the use of a lim-
ited sampling scheme, using different assay techniques to de-
termine the reproducibility of such a strategy in estimating
midazolam AUC. Seventy-three healthy adults received
midazolam as a single intravenous bolus dose. At least eight
plasma samples were collected from each subject and were
assayed using either LC/MS/MS or electron capture gas chro-
matography. Eleven subjects were randomly selected for the
training set using stepwise linear regression to determine re-
lationships between midazolam plasma concentrations and
AUC. Validation of the predictive equations was done using
the remaining 62 subjects. Mean percent error (MPE), mean
absolute error (MAE), and root mean square error (RMSE)
were calculated to determine bias and precision. Based on
the training set, five models were generated with coefficients
of determination ranging from 0.87 to 0.95. Validation
showed that MPE, MAE, and RMSE values were acceptable
for three of the models. Intrasubject reproducibility was good.
In addition, training set data from one institution were able to
predict data from the other two institutions using other assay
techniques. Minimized plasma sampling may provide a sim-
pler method for estimating midazolam AUC for CYP3A
phenotyping. A limited sampling strategy is more convenient
and cost-effective than standard sampling strategies and is
applicable to more than one assay technique.
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to be collected over a 6- to 8-hour period. Generally, at
least eight plasma samples have been used to accu-
rately determine midazolam AUC0-∞.
3-5,7-9 The inconve-
nience and cost of extensive plasma sampling limit the
utility of using intravenous midazolam as an easy and
routine measure of CYP3A metabolic activity. Ideally,
if fewer samples were used, the determination of
midazolam AUC0-∞ would be less expensive and
simpler.
The limited sampling strategy (LSS) was first in-
troduced in 1987 to minimize the number of plasma
samples necessary to estimate AUC values of chemo-
therapeutic agents, immunosuppressive agents,
antimicrobials, and other index substrates.10-17 This ap-
proach has proven to be an effective, validated tool in
monitoring efficacy and toxicity of agents while mini-
mizing the number of blood samples.
To date, no studies have applied the limited sam-
pling strategy method to determine pharmacokinetic
parameters for specific cytochrome P450 phenotyping
agents. In addition, different assay methods are of-
ten used in phenotyping studies. These different as-
say methods may have different accuracy and preci-
sion performance; thus, if LSS is to be applied to
phenotyping probes, assurance that the LSS methods
are applicable to more than one assay method is
important.
The objectives of this study were (1) to evaluate the
use of minimized plasma sampling to determine the
least number of plasma samples necessary to accu-
rately estimate the AUC0-∞ of midazolam following a
single intravenous dose, (2) to validate the developed
models for application with different assay tech-
niques (LC/MS/MS and electron capture gas chroma-
tography) at different institutions, and (3) to deter-
mine if the models give reproducible results in subjects
undergoing repeat phenotyping measurements with
midazolam.
METHODS
Data sets from three separate institutions were used in
the study, and details of the original findings have been
individually reported.6,8,18,19 This study was approved
by the Institutional Review Board at Bassett Healthcare
in Cooperstown, New York (Institution I); the Human
Investigation Review Committee at the New England
Medical Center and Tufts University in Boston (Institu-
tion II); and the Institutional Review Board–Health Sci-
ences at Vanderbilt University (Institution III). Written
informed consent was obtained from all study subjects.
Subjects
Institution I
Thirty-three healthy volunteers were enrolled. Base-
line laboratory measurements (i.e., complete blood
count, serum chemistries, urinalysis) and electrocar-
diogram were obtained prior to study participation.
Each subject underwent a complete physical examina-
tion and medical history to ensure that previously de-
scribed inclusion and exclusion criteria were met.8
Smokers and binge drinkers were excluded. Alcohol
intake was limited to one drink (equivalent to one
12-ounce beer) per day, and no concomitant medica-
tions were allowed. Individuals with liver function
tests (i.e., aspartate aminotransferase, alanine amino-
transferase) greater than 1.5 times the upper limit of
normal, total bilirubin greater than 1.5 mg/dl, or serum
creatinine values not within the normal range (0.6-1.2
mg/dl for men; 0.5-1.0 mg/dl for women) were also
excluded.
Subjects were administered intravenous midazolam
0.025 mg/kg (Versed: 2 mg/ml for injection, Hoffman-
LaRoche, Nutley, NJ) into an antecubital vein over 1
minute. Blood samples (7 ml) were collected through
an intravenous catheter (in the contralateral arm) into
EDTA-containing tubes at predose and 5, 30, 60, 120,
240, 300, and 360 minutes following midazolam ad-
ministration. Ten subjects had five repeated adminis-
trations of single intravenous boluses of midazolam at
2-week intervals. The blood samples were centrifuged;
plasma was harvested and frozen at –80°C until
analysis.
Institution II
Data were obtained from 11 healthy nonsmokers who
did not take any concomitant medications for the dura-
tion of the study. Medical histories, physical examina-
tions, and blood work were obtained for screening.
Subjects received intravenous bolus midazolam 2
mg and had blood samples collected at predose and 15,
30, 45, 60, 90, 120, 150, 180, 240, 300, 360, and 480
minutes following midazolam administration.
Institution III
Twenty-nine healthy volunteers were enrolled. Sub-
jects were nonsmokers who did not take any concomi-
tant medications for the study duration. For screening
purposes, medical histories and physical examinations
were performed and appropriate blood work obtained.
Subjects received a 1 mg intravenous bolus dose of
[15N3]-labeled midazolam. Blood samples were col-
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lected at predose and 5, 10, 15, 30, 60, 90, 120, 180, 240,
300, 360, and 480 minutes following midazolam ad-
ministration. Collected samples were centrifuged, and
plasma was frozen at –20°C until analysis.
Analytical Procedure
At Institutions I and III, midazolam assays were per-
formed by liquid chromatography/tandem mass spec-
trometry (LC/MS/MS) methodology. This analytical
procedure was performed at Oneida Research Services
in Whitesboro, New York, for plasma samples collected
at Institution I,8 and this analytical procedure had an
interday accuracy of –5.7% to 9.2% and precision of
9.9% over nominal values. The LC/MS/MS assay per-
formed at Institution III had an interday variation of
less than 12%.19 Plasma samples were analyzed using
electron capture gas chromatography at Institution II, a
method previously published by Arendt et al.20
Pharmacokinetic Analysis
Midazolam AUC0-∞ (AUCobs) values were determined
using the log-linear trapezoidal rule using the plasma
concentration-time data, with extrapolation of the last
measured concentration to infinity. Institution I used
the pharmacokinetic computer program, TOPFIT 2.0
(Gustav Fisher Verlag, Stuttgart, Germany), for deter-
mining midazolam AUC0-∞. Because plasma samples
were not obtained at 5 minutes after midazolam admin-
istration at Institution II, the 5-minute plasma concen-
tration was extrapolated for each subject using “back
projection” or “stripping technique” principles.21
Pharmacokinetic parameters were determined using
SAS PROC NLIN (SAS Institute, Cary, NC) at Institu-
tion II and the computer program NCOMP at Institution
III.22 Elimination rate constants were calculated from
using linear regression analysis of the terminal portion
of the serum concentration versus time curve. All
pharmacokinetic programs used for analysis are vali-
dated programs.
Data Analysis
Data were used to develop a training set (a set providing
the best equations for prediction of AUC). The training
set equations were applied to the remaining subject
data to validate the prediction equations. All data were
dose normalized to a dose of 1 mg.
Eleven randomly chosen subjects from Institution I
were used as the training set.23 Using stepwise multiple
linear regression, coefficients of determination (r 2 )
were generated from the training set for one-, two-, and
three-variable models to best predict AUC0-∞ values
(AUCpred) of midazolam.
The models were validated using the data from the
remaining 61 subjects. Predicted AUC values (AUCpred)
and observed AUC values (AUCobs) were analyzed, and
then AUC data were log transformed in all cases to nor-
malize the distribution of the data. AUCpred were com-
pared with AUCobs by calculating mean percent error
(MPE) and mean absolute error (MAE) for precision
















































Acceptable limits for precision and bias estimation for
MPE, MAE, and RMSE were set at < 5%, < 10%, and <
15%, respectively.
Ten subjects in the validation set had five repeated
administrations of single IV midazolam boluses at
2-week intervals. MPE, MAE, and RMSE were calcu-
lated to compare intraindividual variability to validate
the reproducibility of the developed models.
To assess if the training set developed using the as-
say from Institution I was applicable to the assay meth-
ods from the other two institutions, data from the 40
subjects from Institutions II and III were analyzed using
the training set to assess predictive ability. MPE, MAE,
and RMSE were calculated to compare variability be-
tween institutions to validate the reproducibility of the
developed models. Analyses were done using SAS
V6.08 and MS Excel (Microsoft Corp., Redmond, WA).
Data are presented as mean standard deviation (SD),
and p-values 0.05 were considered statistically
significant.
RESULTS
Based on data from the training set, three different
models with corresponding r 2 values were generated
(Table I). The 300-minute plasma sample was the best
one-variable model with an r 2 of 0.87. The most accu-
rate two-variable model used time points at 60 and 300
minutes (r 2 = 0.95). The best three-variable model used
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data from 5, 30, and 360 minutes (r 2 = 0.95). Two addi-
tional one- and two-variable models are shown in Table I.
Figures 1 through 3 graphically depict r 2 values for the
best one-, two- and three- variable models by compar-
ing AUCobs versus AUCpred.
Using the validation set, the percentages of mean
percent error (MPE), mean absolute error (MAE), and
root mean square error (RMSE) values were calculated
for precision and bias, as shown in Table II. When
AUCpred and AUCobs data were normalized by log trans-
formation, each sampling schema met acceptable pre-
cision and bias limits. The percentage errors were also
calculated for five repeated visits at 2-week intervals
for 10 subjects from Institution I to evaluate the
reproducibility of errors using the models developed
from the first visit data (see Table III). Data in Table III
are for Visits 2 and 3. Results were similar for Visits 4, 5,
and 6 (data not shown). Evaluation of the predictive
equations showed good intrasubject reproducibility.
Table IV shows the results of the analysis using the
training set data from Institution I to predict AUC from
Institutions II and III. As noted in Table IV, good predic-
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Table I Summary of r 2 Values for Different Plasma Sampling Strategies for One,
Two, and Three Midazolam Plasma Samples: Training Set (11 subjects)
Model Plasma Sampling Times (min) Sampling Strategy for AUCpred r
2
1 300 653.393C300 + 954.2257 0.87
2 360 968.526C360 + 855.8843 0.78
3 60, 300 65.55C60 + 506.283C300 + 626.688 0.95
4 30, 360 40.355C30 + 798.579C360 + 528.352 0.93
5 5, 30, 360 12.265C5 + 24.0024C30 + 808.1387C360 + 430.4797 0.95

























Figure 1. Predicted versus observed AUC0-∞ for plasma samples ob-
tained at 300 minutes following midazolam administration. Cn =
midazolam concentration obtained at specified time n (min) follow-
ing a single intravenous dose. AUC0-∞ = area under the curve extrapo-

























Figure 2. Predicted versus observed AUC0-∞ for plasma samples ob-
tained at 60 and 300 minutes following midazolam administration.
Cn = midazolam concentration obtained at specified time n (min) fol-
lowing a single intravenous dose. AUC0-∞ = area under the curve ex-

























Figure 3. Predicted versus observed AUC0-∞ for plasma samples ob-
tained at 5, 30, and 360 minutes following midazolam administra-
tion. Cn = midazolam concentration obtained at specified time n
(min) following a single intravenous dose. AUC0-∞ = area under the
curve extrapolating from the last measured concentration to infinity.
tive ability was seen using the training set from Institu-
tion I to predict data from the two other institutions and
different assays.
DISCUSSION
This study was conducted to explore the possibility of
applying LSS to CYP3A phenotyping with midazolam,
validate this methodology with different assay tech-
niques, and determine if the derived models were re-
producible. Historically, LSS proved to be an effec-
tive tool in monitoring the safety and efficacy of
chemotherapeutic agents by minimizing the number of
blood samples necessary to evaluate AUC.25-28 AUC is a
useful parameter that is quantitatively related to the
myelosuppressive effects of these agents. Evaluation of
such detailed pharmacokinetics requires multiple
plasma sampling (e.g., 16 blood samples with
vinblastine), which is usually not feasible in large num-
bers of patients.
Using a limited number of samples to evaluate the
pharmacokinetic profile of agents is more attractive
than multiple plasma sampling. Scavone et al13 vali-
dated the use of two points at 2 and 6 hours versus 3
and 6 hours to assess the elimination half-life (r = 0.87
and r = 0.84) and clearance (r = 0.97 and r = 0.97) of
acetaminophen. That study, however, overestimated
clearance and volume of distribution by approximately
13% and 14%. The authors concluded that distribution
must have contributed significantly to total AUC, as
previously shown in an earlier study with antipyrine.12
The method of minimized plasma sampling uses
stepwise linear regression to determine optimal con-
centration time points in a model derived from a train-
ing data set to accurately predict pharmacokinetic pa-
rameters such as AUC. The utility of the LSS method
was first illustrated with vinblastine. With only two
time points, Ratain and Vogelzang10 were able to suc-
cessfully estimate total AUC with minimal error using
stepwise multiple regression analysis. The correlation
380 • J Clin Pharmacol 2002;42:376-382
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Table II Percentage Errors Normalized via Log Transformation of AUCpred and AUCobs for Precision
and Bias for One, Two, and Three Midazolam Plasma Samples: Validation Set (62 subjects)
Model (time points) Log AUCpred Range Log AUCpred %MPE %MAE %RMSE
300 min 3.43 ± 0.15 3.14-3.7 1.0 3.3 0.4
60, 300 min 3.39 ±0.14 3.14-3.65 0.1 1.5 1.8
5, 30, 360 min 3.45 ± 0.16 3.16-3.71 1.7 2.9 4.8
Acceptable limits < 5% < 10% < 15%
Observed log AUC = 3.38 ± 0.18 (range: 2.93-3.71). MPE, mean percent error; MAE, mean absolute error; RMSE, root mean square error; AUC, area under the se-
rum concentration time curve from 0 to infinity.
Table III Percentage Errors Normalized via Log
Transformation for Precision and Bias for One,
Two, and Three Midazolam Plasma Samples
from Repeated Visits (2 and 3) for 10 Subjects
Mean Mean Root Mean
Percent Absolute Square
Time Postdose (min) Error Error Error
Visit 2
300 5.0 5.0 5.5
60, 300 6.8 6.8 7.5
5, 30, 360 6.6 6.6 7.3
Visit 3
300 3.1 3.8 4.3
60, 300 6.4 6.4 7.0
5, 30, 360 6.0 6.0 6.6
Acceptable limit < 5% < 10% < 15%
Table IV Percentage Errors Normalized via Log
Transformation for Precision and Bias for One,
Two, and Three Midazolam Plasma Samples Using
Training Set (11 subjects from Institution 1) to Predict
Data from 40 Subjects from Institutions II and III
Model (time points) %MPE %MAE %RMSE
300 min 1.4 4.2 5.8
60, 300 min 0.2 0.2 2.0
5, 30, 360 min 2.5 3.7 5.8
Acceptable limits < 5% < 10% < 15%
MPE, mean percent error; MAE, mean absolute error; RMSE, root mean
square error; AUC, area under the serum concentration time curve from 0 to
infinity.
coefficient was > 0.85 at time points of 1 hour or later
following vinblastine infusion, whereas only a modest
correlation was demonstrated for plasma samples ob-
tained between 5 and 20 minutes (r < 0.58). The two
best correlation coefficients (r = 0.97) were at 10 hours
and 36 hours. The model was highly predictive of
AUC, illustrated by the predictive error of 13%. Other
drugs for which minimized plasma sampling has
proven effective at predicting AUC include cyclo-
phosphamide, doxorubicin, etoposide, carboplatin,
irinotecan, antipyrine, and acetaminophen.11-13,25-27,29-32
Similar success has been found in predicting AUC by
using limited plasma sampling to monitor the efficacy
and toxicity profiles of various immunosuppressives,
such as mycophenolic acid and cyclosporine.33-35
Validation of the study models was accomplished by
calculating percentage errors. Percentage errors, such
as mean percent error and mean absolute error, provide
information about the precision and bias of the predic-
tive value (AUCpred) when using derived models to esti-
mate AUC. Absolute errors (i.e., MAE) represent the
precision of the predicted value. The mean percentage
errors (i.e., MPE) describe the prediction bias.24 These
values can serve as a tool to assess the model that pre-
dicts the mathematically derived parameter with the
most precision and the least bias (the error percentages
with the lowest values represent the best models). Gen-
erally, the limits for these errors are not specific values
for each study, and the majority of limited sampling
studies report error percentages that are < 5% for MPE, <
10% for MAE, and < 15% for RMSE.36,37
This study examined the use of minimized plasma
sampling with intravenous midazolam. Three of the
models generated from our training set using one-,
two-, or three-plasma samples provided r 2 values of
0.87. The two- and three-variable models illustrated
the best r 2 value (r 2 = 0.95). When the AUC data were
normalized by log transformation, each model showed
excellent precision with minimal bias. Although all
models perform well, the three-point model will per-
form best in instances when an assay measurement
may be erroneous since the erroneous point will be-
come evident.
The one-, two-, and three-variable models validated
in 62 subjects were also validated in a subset of these
subjects (n = 10) to evaluate the reproducibility of the
derived models to the same individuals at different
time intervals. The models projected acceptable mean
values for MPE, MAE, and RMSE, respectively. These
models, therefore, expressed acceptable intrasubject
reproducibility.
Another question is whether or not training models
produced using data from one institution or assay
method can be used to predict data from other institu-
tions. The one-, two-, and three-variable models devel-
oped in 11 subjects from Institution I were evaluated in
the 40 subjects from Institutions II and III to assess the
reproducibility of the models. The models projected
acceptable mean values for MPE, MAE, and RMSE,
respectively.
A limitation of this study was that a small sample
size of healthy volunteers was used to develop the
models and may not reflect ascertainment of AUC over
the entire population or in nonhealthy individuals.
These models are also not applicable to pediatric sub-
jects as children exhibit different midazolam pharma-
cokinetic parameters from adults.38 Finally, the
schedules for blood sampling differed somewhat
among institutions, compromising the accuracy for
predicted AUC values. Further prospective studies
with larger numbers and different types of individuals
are needed to better characterize these models.
A strength of this study is that it validated models
developed by one institution using one assay method
with plasma samples quantified by different assay
techniques. This validation indicates that these models
may be used in institutions that use various assay tech-
niques. Most minimized sampling studies use a single
assay method or do not report the types of assay tech-
niques used in the studies. In the current study, the
models derived from one assay technique were appli-
cable to different assays, making these models more
universal to other institutions.
Minimized plasma sampling provides an accurate
and precise method for evaluating midazolam AUC in
adults. The use of LSS may be a more convenient,
cost-effective, and useful method for measuring
hepatic CYP3A activity with midazolam.
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